Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Everence Capital Management Inc.

Everence Capital Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,741 shares of the biopharmaceutical company’s stock after acquiring an additional 70 shares during the period. Everence Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,286,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Markel Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock worth $56,083,000 after buying an additional 1,000 shares during the period. Cibc World Market Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after buying an additional 86 shares during the period. Blair William & Co. IL boosted its position in shares of Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after buying an additional 222 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 23.1% during the first quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 93 shares during the period. Finally, Baird Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 100.9% during the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after purchasing an additional 18,345 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 over the last ninety days. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.5 %

NASDAQ:REGN traded down $4.42 during trading hours on Tuesday, reaching $894.14. The company’s stock had a trading volume of 608,448 shares, compared to its average volume of 492,548. The company has a market cap of $98.14 billion, a price-to-earnings ratio of 25.86, a price-to-earnings-growth ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The business’s 50-day moving average is $956.81 and its 200-day moving average is $889.95. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the prior year, the company earned $10.96 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $970.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.